Anteris Technologies Global Corp. Common Stock (AVR)

• Market cap: $251M
• 1 day: 2.05%
• 5 days: -6.82%
• 1 month: -12.77%
• 3 months: 26.73%
• 6 months: 24.46%
• Year to date: 25.59%
• 1 year: 24.46%
• 5 years: 24.46%
• 10 years: 24.46%
• Sector: Healthcare
• Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies

About: Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

45.27% more ownership

Funds ownership: 0% [Q3] → 45.27% (+45.27%) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 29% upside
• Avg. target: $16.50 137% upside
• High target: $22 216% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Frank Takkinen 45% 1-year accuracy 9 / 20 met price target	187% upside $20	Buy Initiated	8 Jan 2025
TD Cowen Joshua Jennings 37% 1-year accuracy 7 / 19 met price target	115% upside $15	Buy Initiated	7 Jan 2025
Cantor Fitzgerald Ross Osborn 46% 1-year accuracy 21 / 46 met price target	29% upside $9	Overweight Initiated	7 Jan 2025
Barclays Matt Miksic 63% 1-year accuracy 26 / 41 met price target	216% upside $22	Overweight Initiated	7 Jan 2025